Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Irene De Guidi"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Despite the high energetic cost of the reduction of sulfate to H2S, required for the synthesis of sulfur-containing amino acids, some wine Saccharomyces cerevisiae strains have been reported to produce excessive amounts of H2S during alcohol
Externí odkaz:
https://doaj.org/article/4d6b3d2896b54bf481fa8e1a382d7437
Autor:
Viviana Cafiso, Stefano Stracquadanio, Flavia Lo Verde, Irene De Guidi, Alessandra Zega, Giuseppe Pigola, Stefania Stefani
Publikováno v:
Frontiers in Microbiology, Vol 11 (2020)
Daptomycin (DAP) is one of the last-resort treatments for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and vancomycin-intermediate S. aureus (VISA) infections. DAP resistance (DAP-R) is multifactorial and mainly related to cell
Externí odkaz:
https://doaj.org/article/84a54434652f42f3a3aceb21df0746c7
Publikováno v:
Fermentation, Vol 7, Iss 4, p 213 (2021)
Hydrogen sulfide (H2S) is the main volatile sulfur compound produced by Saccharomycescerevisiae during alcoholic fermentation and its overproduction leads to poor wine sensory profiles. Several factors modulate H2S production and winemakers and resea
Externí odkaz:
https://doaj.org/article/ef88423840254bcfab5cf1a8eeb5c2f7
Publikováno v:
Current Opinion in Food Science. 51:101032
Autor:
Stefania Stefani, Stefano Stracquadanio, Alessandra Zega, Giuseppe Pigola, Viviana Cafiso, Irene De Guidi, Flavia Lo Verde
Publikováno v:
Frontiers in Microbiology, Vol 11 (2020)
Daptomycin (DAP) is one of the last-resort treatments for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and vancomycin-intermediate S. aureus (VISA) infections. DAP resistance (DAP-R) is multifactorial and mainly related to cell
Autor:
Viviana, Cafiso, Stefano, Stracquadanio, Flavia, Lo Verde, Irene, De Guidi, Alessandra, Zega, Giuseppe, Pigola, Stefania, Stefani
Publikováno v:
Frontiers in Microbiology
Daptomycin (DAP) is one of the last-resort treatments for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and vancomycin-intermediate S. aureus (VISA) infections. DAP resistance (DAP-R) is multifactorial and mainly related to cell